Mostrando 2 resultados de: 2
Área temáticas
Enfermedades(2)
Farmacología y terapéutica(2)
Cirugía y especialidades médicas afines(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(2)
ODS 17: Alianzas para lograr los objetivos(1)
ODS 1: Fin de la pobreza(1)
Origen
scopus(2)
The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus
ReviewAbstract: Background: In Latin America, the medical attention directed to systemic autoimmune diseases competePalabras claves:Autores:Cardiel M.H., Cervera R., Claudio M. Galarza-Maldonado, Doukh N., Kourilovitch M.R., Molineros J.E., Soroka N.F., Yagur V.Y., Zurita L.Fuentes:scopusShould rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
ArticleAbstract: The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monPalabras claves:CD20, Pharmacogenomics, Rheumatoid Arthritis, rituximab, Sjögren's syndrome, systemic lupus erythematosusAutores:Anaya J.M., Claudio Galarza, Mantilla R.D., Pineda-Tamayo R., Rojas-Villarraga A., Rueda J.C., Tobón G.J., Valencia D., Zurita L.Fuentes:scopus